Phase 2 Trial of Maintenance Vigil for High Risk Stage IIIb-IV Ovarian Cancer



Status:Active, not recruiting
Conditions:Ovarian Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/22/2019
Start Date:February 2015
End Date:January 2020

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy

This is a multicenter, randomized, double-blind, placebo-controlled, Phase 2 study of
maintenance Vigil Ovarian (gemogenovatucel-T) in women with Stages IIIb, IIIc or IV
high-grade papillary serous/clear cell/endometrioid ovarian, fallopian tube or primary
peritoneal cancer. Subjects will have had a minimum of 4 and a maximum of 12 doses of Vigil
prepared and stored from ovarian tumor cells obtained at the time of primary surgical
debulking or initial diagnostic/evaluative laparoscopy (tissue for immunotherapy manufacture
must be procured prior to initiation of neoadjuvant chemotherapy). An equal number of placebo
doses will manufactured. Subjects will have achieved a clinically defined complete response
following primary surgery and adjuvant chemotherapy.

This is a multicenter, randomized, double-blind, placebo-controlled, Phase 2 study of
maintenance Vigil Ovarian (gemogenovatucel-T) engineered autologous tumor cells (EATC) in
women with Stage IIIb, IIIc or IV high-grade papillary serous/ clear cell / endometrioid
ovarian, fallopian tube or primary peritoneal cancer. Subjects will have had a minimum of 4
and a maximum of 12 doses of Vigil prepared and stored from ovarian tumor cells obtained at
the time of primary surgical debulking or initial diagnostic / evaluative laparoscopy (tissue
for immunotherapy manufacture must be procured prior to initiation of neoadjuvant
chemotherapy). An equal number of placebo doses will be manufactured. Subjects will have
achieved a clinically defined complete response following primary surgery and adjuvant
chemotherapy.

Investigational treatment must start no less than 3 weeks and no more than 8 weeks following
completion of chemotherapy.

Approximately 86 subjects will be randomized 1:1 to receive either monthly intradermal Vigil
or placebo for at least 4 to a maximum of 12 administrations. Randomization will be
stratified by (i) extent of surgical cytoreduction (complete/microscopic versus macroscopic
residual disease) and (ii) neoadjuvant versus adjuvant chemotherapy. The objective is
determining RFS of subjects randomized to Vigil versus placebo.

Inclusion Criteria

Subjects will be eligible for tissue procurement for the Vigil manufacturing process if
they meet all of the following criteria:

1. Presumptive Stage IIIb, IIIc or IV high-grade papillary serous/clear cell/endometrioid
ovarian, fallopian tube or primary peritoneal cancer.

2. No chemotherapy prior or investigational agents prior to tissue acquisition for Vigil
manufacture.

3. No other malignancy (excluding surgically cured nonmelanoma carcinomas of the skin and
carcinoma in situ cervix) unless in remission for ≥ 2 years.

4. Anticipated availability of a cumulative mass of ~30 grams tissue ("golf-ball" size or
approximately 3cm disease on CT scan) at time of diagnostic laparoscopy or primary
surgical debulking. Infiltrating lumen (bowel, fallopian tube, urethra) tissue should
not be used as Vigil immunotherapy material to minimize risk of bacterial
contamination.

5. ECOG performance status (PS) 0-2 prior to diagnostic laparoscopy or debulking
laparotomy.

6. No prior history of hypersensitivity reactions (HSR) with taxanes or platinums.

7. No prior history of allergies or sensitivities to gentamicin.

8. Female, 18 years of age or older.

9. Ability to understand and the willingness to sign a written informed consent document
for tissue harvest.

Subjects will be registered in this study if they meet all of the following inclusion
criteria:

1. Histologically confirmed Stage IIIb, IIIc or IV high-grade papillary serous/clear
cell/endometrioid ovarian, fallopian tube or primary peritoneal.

2. Completion of primary surgical debulking including hysterectomy and bilateral salpingo
oophorectomy, and at least 5 but no more than 8 cycles of platinum / taxane adjuvant
chemotherapy or chemotherapy as per Category 1 recommendations of the NCCN guidelines,
including 5-8 cycles adjuvant intraperitoneal + intravenous (IP/IV) chemotherapy, or
5-8 cycles of intravenous chemotherapy divided and administered as neoadjuvant and
adjuvant therapy flanking primary debulking surgery.

3. Clinically defined complete response (cCR) following completion of primary surgical
debulking and eligible chemotherapy. cCR defined as no evidence of malignancy on chest
x-ray (CT scan is acceptable) and CT scan or MRI of the abdomen and pelvis, normal
physical examination, CA-125 antigen level ≤ 35 U/ml (assessed ≥ 2 weeks following
removal of catheter in subjects receiving intraperitoneal/intravenous chemotherapy)
and no findings on physical examination or symptoms suggestive of active cancer.

4. Subjects must have initiated adjuvant chemotherapy no more than 8 weeks following
primary debulking surgery.

5. Successful manufacturing of at least 4 doses (vials) of Vigil and placebo.

6. Recovered from all clinically relevant toxicities related to prior therapy (including
neuropathy ≤Grade 2).

7. ECOG performance status (PS) 0-1.

8. Normal organ and marrow function as defined below: Absolute granulocyte count ≥
1,500/mm^3, Absolute lymphocyte count ≥ 500/mm^3, Platelets ≥ 75,000/mm^3, Total
bilirubin ≤ 2 mg/dL, AST(SGOT)/ALT(SGPT)≤ 2x institutional upper limit of normal,
Creatinine < 1.5 mg/dL

9. Ability to understand and the willingness to sign a written informed protocol specific
consent.

Exclusion Criteria:

Subjects will be excluded from this study if they meet any of the following criteria (at
the time of tissue procurement or at randomization):

1. Surgery involving general anesthesia, radiotherapy, immunotherapy, or investigational
agents within 4 weeks prior to randomization.

2. Histologically confirmed papillary serous adenocarcinoma of the uterus or disease
involving myometrium/endometrium.

3. Systemic immunosuppressive therapy within 14 days of randomization.

4. Subjects requiring chronic steroid or immunosuppressive regimens are excluded except
inhaled / intranasal steroids and short term systemic steroids <30 days duration and
≤0.25 mg/kg prednisone-equivalent per day are allowed.

5. Congestive heart failure (NYHA Class II, III, or IV), unstable angina, ventricular or
hemodynamically significant atrial arrhythmia, or cardiovascular disease such as
stroke or myocardial infarction (current or within the past 6 months).

6. Psychiatric illness/social situations that would limit compliance with study
requirements.

7. Subjects with history of brain metastases.

8. Subjects with known HIV or chronic Hepatitis B or C infection.

9. Prior solid organ or bone marrow transplant.

10. History of or active autoimmune disease (e.g., autoimmune neutropenia,
thrombocytopenia, or hemolytic anemia, systemic lupus erythematosus, Sjogren's
syndrome, scleroderma, myasthenia gravis, Goodpasture's syndrome, Addison's disease,
Hashimoto's thyroiditis, or Graves disease). Persons with vitiligo are not excluded.
Diabetics are not excluded if the condition is well controlled.
We found this trial at
26
sites
Lebanon, New Hampshire 03756
Principal Investigator: Leslie DeMars, MD
Phone: 603-653-3537
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Sarah F. Adams, MD
Phone: 505-925-0387
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Parviz Hanjani, MD
Phone: 215-885-0220
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A Ghamande, MD
Phone: 706-721-4805
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Israel Zighelboim, MD
Phone: 484-526-5190
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
801 North 29th Street
Billings, Montana 59107
406-238-2500
Principal Investigator: Erin Stevens, MD
Phone: 406-435-7415
Billings Clinic Based in Billings, Montana, Billings Clinic is a community-governed health care organization consisting...
?
mi
from
Billings, MT
Click here to add this to my saved trials
Boston, Massachusetts 02215
Principal Investigator: Neil S Horowitz, MD
Phone: 617-582-7738
?
mi
from
Boston, MA
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
Principal Investigator: Eric Eisenhauer, MD
Phone: 513-584-4528
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Minal Barve, MD
Phone: 972-566-3000
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: Jayanthi Lea, MD
Phone: 214-648-7094
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48202
Principal Investigator: Adnan Munkarah, MD
Phone: 313-916-6781
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Durham, North Carolina 27710
Principal Investigator: Stephanie L. Gaillard, MD, PhD
Phone: 919-684-3780
?
mi
from
Durham, NC
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Jeffrey Elder, MD
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: Amir Jazaeri, MD
Phone: 713-745-4539
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Irvine, California 92618
Principal Investigator: Devansu Tewari, MD
Phone: 949-932-5695
?
mi
from
Irvine, CA
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
Principal Investigator: Fred R Ueland, MD
Phone: 859-257-3379
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Brian Slomovitz, MD
Phone: 305-243-1000
?
mi
from
Miami, FL
Click here to add this to my saved trials
1660 Springhill Avenue
Mobile, Alabama 36604
(251) 665-8000
Principal Investigator: Rodney Rocconi, MD
Phone: 251-665-8000
University of South Alabama Mitchell Cancer Institute USA Mitchell Cancer Institute (MCI) is located in...
?
mi
from
Mobile, AL
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Principal Investigator: Kathleen Moore, MD
Phone: 405-271-8777
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Principal Investigator: Peter C Morris, MD
Phone: 402-354-7939
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
Principal Investigator: Christina Chu, MD
Phone: 215-728-4300
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: John K Chan, MD
Phone: 415-600-3241
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Spokane, Washington 99218
Principal Investigator: Elizabeth Grosen, MD
Phone: 509-228-1689
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Tacoma, Washington 98405
Principal Investigator: Bahman Saffari, MD
Phone: 253-426-6882
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Robert Wenham, MD
Phone: 813-745-7272
?
mi
from
Tampa, FL
Click here to add this to my saved trials
West Palm Beach, Florida 33401
Principal Investigator: Howard M Goodman, MD
Phone: 561-472-1696
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials